Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants

Ricardo S. De Souza, Orlando W Gomez-Marin, Gwendolyn B Scott, Silvia Guasti, Mary Jo O'Sullivan, Ricardo Hugo Oliveira, Charles D Mitchell

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To determine the influence of prenatal zidovudine (ZDV) prophylaxis on the course of HIV-1 infection in children by comparing the clinical outcome of infants born to HIV-1-seropositive mothers who did versus those who did not receive ZDV during pregnancy. Methods: Medical records of HIV-1-seropositive mothers and their infants were reviewed retrospectively. Participants were divided according to maternal ZDV use: no ZDV (n = 152); ZDV (n = 139). The main outcome measure was rapid disease progression (RPD) in the infant, defined as occurrence of a category C disease or AIDS-related death before 18 months of age. Results: HIV vertical transmission rates were significantly different (no ZDV versus ZDV: 22.3% versus 12.2%; p = .034). Among infected infants, the RPD rote was 29.4% in the no ZDV group compared with 70.6% in the ZDV group (p = .012), and prematurity was significantly associated with a higher risk of RPD (p = .027). Conclusions: The rote of RPD was significantly higher among perinatally infected infants born to HIV-infected mothers treated with ZDV than among infected infants born to untreated mothers. The decreased proportion of infected infants with nonrapid disease progression in the former group might be related to the ability of ZDV to block intrapartum transmission preferentially and also to nonrapid disease progression resulting from intrapartum transmission.

Original languageEnglish
Pages (from-to)154-161
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume24
Issue number2
StatePublished - Jun 1 2000

Fingerprint

Zidovudine
Disease Progression
HIV-1
Mothers
HIV
Aptitude
HIV Infections
Medical Records
Acquired Immunodeficiency Syndrome
Outcome Assessment (Health Care)

Keywords

  • Perinatal HIV-1 infection
  • Prematurity
  • Rapid disease progression
  • Timing of transmission
  • Zidovudine

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants. / De Souza, Ricardo S.; Gomez-Marin, Orlando W; Scott, Gwendolyn B; Guasti, Silvia; O'Sullivan, Mary Jo; Oliveira, Ricardo Hugo; Mitchell, Charles D.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 24, No. 2, 01.06.2000, p. 154-161.

Research output: Contribution to journalArticle

De Souza, RS, Gomez-Marin, OW, Scott, GB, Guasti, S, O'Sullivan, MJ, Oliveira, RH & Mitchell, CD 2000, 'Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants', Journal of Acquired Immune Deficiency Syndromes, vol. 24, no. 2, pp. 154-161.
De Souza RS, Gomez-Marin OW, Scott GB, Guasti S, O'Sullivan MJ, Oliveira RH et al. Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants. Journal of Acquired Immune Deficiency Syndromes. 2000 Jun 1;24(2):154-161.
De Souza, Ricardo S. ; Gomez-Marin, Orlando W ; Scott, Gwendolyn B ; Guasti, Silvia ; O'Sullivan, Mary Jo ; Oliveira, Ricardo Hugo ; Mitchell, Charles D. / Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants. In: Journal of Acquired Immune Deficiency Syndromes. 2000 ; Vol. 24, No. 2. pp. 154-161.
@article{75de9f7cc727454faeec6cb52c09a4df,
title = "Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants",
abstract = "Objective: To determine the influence of prenatal zidovudine (ZDV) prophylaxis on the course of HIV-1 infection in children by comparing the clinical outcome of infants born to HIV-1-seropositive mothers who did versus those who did not receive ZDV during pregnancy. Methods: Medical records of HIV-1-seropositive mothers and their infants were reviewed retrospectively. Participants were divided according to maternal ZDV use: no ZDV (n = 152); ZDV (n = 139). The main outcome measure was rapid disease progression (RPD) in the infant, defined as occurrence of a category C disease or AIDS-related death before 18 months of age. Results: HIV vertical transmission rates were significantly different (no ZDV versus ZDV: 22.3{\%} versus 12.2{\%}; p = .034). Among infected infants, the RPD rote was 29.4{\%} in the no ZDV group compared with 70.6{\%} in the ZDV group (p = .012), and prematurity was significantly associated with a higher risk of RPD (p = .027). Conclusions: The rote of RPD was significantly higher among perinatally infected infants born to HIV-infected mothers treated with ZDV than among infected infants born to untreated mothers. The decreased proportion of infected infants with nonrapid disease progression in the former group might be related to the ability of ZDV to block intrapartum transmission preferentially and also to nonrapid disease progression resulting from intrapartum transmission.",
keywords = "Perinatal HIV-1 infection, Prematurity, Rapid disease progression, Timing of transmission, Zidovudine",
author = "{De Souza}, {Ricardo S.} and Gomez-Marin, {Orlando W} and Scott, {Gwendolyn B} and Silvia Guasti and O'Sullivan, {Mary Jo} and Oliveira, {Ricardo Hugo} and Mitchell, {Charles D}",
year = "2000",
month = "6",
day = "1",
language = "English",
volume = "24",
pages = "154--161",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants

AU - De Souza, Ricardo S.

AU - Gomez-Marin, Orlando W

AU - Scott, Gwendolyn B

AU - Guasti, Silvia

AU - O'Sullivan, Mary Jo

AU - Oliveira, Ricardo Hugo

AU - Mitchell, Charles D

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Objective: To determine the influence of prenatal zidovudine (ZDV) prophylaxis on the course of HIV-1 infection in children by comparing the clinical outcome of infants born to HIV-1-seropositive mothers who did versus those who did not receive ZDV during pregnancy. Methods: Medical records of HIV-1-seropositive mothers and their infants were reviewed retrospectively. Participants were divided according to maternal ZDV use: no ZDV (n = 152); ZDV (n = 139). The main outcome measure was rapid disease progression (RPD) in the infant, defined as occurrence of a category C disease or AIDS-related death before 18 months of age. Results: HIV vertical transmission rates were significantly different (no ZDV versus ZDV: 22.3% versus 12.2%; p = .034). Among infected infants, the RPD rote was 29.4% in the no ZDV group compared with 70.6% in the ZDV group (p = .012), and prematurity was significantly associated with a higher risk of RPD (p = .027). Conclusions: The rote of RPD was significantly higher among perinatally infected infants born to HIV-infected mothers treated with ZDV than among infected infants born to untreated mothers. The decreased proportion of infected infants with nonrapid disease progression in the former group might be related to the ability of ZDV to block intrapartum transmission preferentially and also to nonrapid disease progression resulting from intrapartum transmission.

AB - Objective: To determine the influence of prenatal zidovudine (ZDV) prophylaxis on the course of HIV-1 infection in children by comparing the clinical outcome of infants born to HIV-1-seropositive mothers who did versus those who did not receive ZDV during pregnancy. Methods: Medical records of HIV-1-seropositive mothers and their infants were reviewed retrospectively. Participants were divided according to maternal ZDV use: no ZDV (n = 152); ZDV (n = 139). The main outcome measure was rapid disease progression (RPD) in the infant, defined as occurrence of a category C disease or AIDS-related death before 18 months of age. Results: HIV vertical transmission rates were significantly different (no ZDV versus ZDV: 22.3% versus 12.2%; p = .034). Among infected infants, the RPD rote was 29.4% in the no ZDV group compared with 70.6% in the ZDV group (p = .012), and prematurity was significantly associated with a higher risk of RPD (p = .027). Conclusions: The rote of RPD was significantly higher among perinatally infected infants born to HIV-infected mothers treated with ZDV than among infected infants born to untreated mothers. The decreased proportion of infected infants with nonrapid disease progression in the former group might be related to the ability of ZDV to block intrapartum transmission preferentially and also to nonrapid disease progression resulting from intrapartum transmission.

KW - Perinatal HIV-1 infection

KW - Prematurity

KW - Rapid disease progression

KW - Timing of transmission

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0034209891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034209891&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 154

EP - 161

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -